PubMed HealthSearch

Biomedical subjects

M Witkowska

Publications and source records attributed to M Witkowska.

At least 19 recordsLinked to original sources

[The effect of hypotensive drugs on left ventricular mass and diastolic function].

Chronic left ventricular hypertrophy (LVH) is associated with depressed contractile performance, abnormal compliance of the chamber, and ultimately, the development of a left ventricular failure. Thus the presence of LVH carries a particularly ominous prognosis in patients with essential hypertension. Finally, regression of LVH appears to be a worthwhile goal of an antihypertensive therapy along with blood pressure control. Of particular importance, is whether the functional derangements associated with hypertrophy will also be reversed. The present study was undertaken to determine whether antihypertensive therapy reduced ventricular mass, and whether these changes were accompanied by improved diastolic function. 47 patients with mild-to-moderate essential hypertension were divided into two groups. Group I--included 21 patients whose blood pressure responded to nifedipine monotherapy. Group II--included 26 patients whose normalization of blood pressure required combined therapy with nifedipine and metoprolol. 40 healthy volunteers comprised a control group. To assess the effects of antihypertensive therapy on the heart, left ventricular mas (LVM), systolic and diastolic function, by M-mode, 2-D and pulsed wave Doppler echocardiography had been evaluated. Measurements were performed before therapy and every 3rd month during first year, and every 40th month during the second year of observation. RESULTS. At baseline all hypertensive patients had significantly increased LVM compared to the controls. Indexes of systolic function in studied patients were normal, while indexes of LV diastolic filling were significantly abnormal compared to the controls. In the group treated with nifedipine, starting from the 9th month of observation, small but significant decrease in posterior wall thickness was noted but LVM did not change during the whole time of the observation. Similarly, there was no significant change in indexes of left ventricular diastolic filling. Contrary to patients treated with nifedipine, in group of patients treated with combination of nifedipine and metoprolol, significant reduction of LVM and improvement of LV diastolic filling was observed. Of particular interest was the fact, that improvement in diastolic, performance appeared earlier, and preceded regression of LVM. Most striking was the improvement in Ev/Av ratio which increased by 16% after 6 months and by 35% after 24 months of the therapy. CONCLUSION. 1. Combined therapy with nifedipine and metoprolol contrary to monotherapy with nifedipine alone, results in the regression of left ventricular mass and the improvement of left ventricular diastolic function. 2. Improvement of left ventricular diastolic function appears earlier, preceding the regression of left ventricular hypertrophy.

Adult

[Biochemical indicators of coronary arteriosclerosis].

In 251 patients undergoing cardiac catheterization, plasma levels of lipids, lipoproteins, apoproteins and nonlipid risk factors as fibrinogen, fibrinolysis time, glucose and uric acid in blood were correlated with the incidence and severity of coronary artery disease (CAD). There were significant differences between CAD group and controls and between men and women with CAD with respect to the mean lipid values. Among the nonlipid risk factors fibrinogen concentration in CAD patients was significantly higher than in controls. In univariate analysis in men, score for the severity of atherosclerosis was strongly related to the apoB and LDL concentration, less to the HDL and fibrinogen levels and to ratios of total cholesterol/HDL and LDL/HDL. In women severity of the disease correlated with apoB, fibrinolysis time, fibrinogen and triglyceride levels. By stepwise multivariate analysis, in both men and women, apoB was selected as the best discriminator between CAD patients and controls. The results of the study indicate that the levels of apoB may be a more accurate predictor of the severity of CAD than the other biochemical risk factors. The presented data also suggests an association between increased fibrinogen concentration, reduced fibrinolytic capacity and CAD. The values of apoB and fibrinogen as indicators of cardiovascular risk should be assessed in prospective studies.

Adult

[Does chronic therapy of hypertension with acebutolol or hydrochlorothiazide effect coronary risk factors?].

In 78 patients with mild or moderate hypertension, effect of acebutolol and hydrochlorothiazide on plasma lipids, lipoproteins, fibrinogen and plasma fibrinolysis time were investigated. 42 patients were treated with acebutolol for 18 months and 36 with hydrochlorothiazide for 24 months. It was shown that neither acebutolol nor hydrochlorothiazide induced significant alterations in investigated biochemical risk factors. The possible causes of controversy encountered in literature and analysis of factors which may influence the character and severity of metabolic disorders resulting from antihypertensive therapy were discussed.

Acebutolol

[Effect of long-term treatment with propranolol or hydrochlorothiazide on biochemical risk factors of coronary disease in patients with hypertension].

In 59 patients with mild or moderate essential hypertension effects of propranolol and hydrochlorothiazide on serum lipids, fibrynogen, glucose and uric acid concentrations as well as serum euglobulins fibrynolysis time were studied. 36 patients received propranolol and 23 subjects hydrochlorothiazide. Follow-up time was 1 year. Statistically significant increases of serum triglycerides, fibrynogen, levels and total cholesterol/HDL cholesterol LDH/HDL indices in comparison with their initial values were stated in a propranolol group. Significant serum cholesterol increase after 6 month therapy was the most substantial metabolic change in a hydrochlorothiazide group. Alterations of lipids indices in both groups were especially intensive in patients with pretreatment stated disturbances of lipids metabolism.

Adult

Pharmacological properties of new heterocyclic derivatives of 1,5-benzodiazepine.

Sixteen new heterocyclic 1,5-benzodiazepine derivatives (compounds AN8-AN24) were screened for their central action. Compounds AN8-AN10 and AN17 strongly antagonized the action of pentetrazol, compounds AN10, AN14-AN17 and AN22 had potent antiserotonin properties, and compounds AN10, AN19, AN20 and AN23 markedly potentiated the action of DOPA.

Animals